A rising incidence of drug resistance caused by the advanced L858R/T790M/C797S triple mutation in NSCLC escalates the urge for the development of the fourth generation of EGFR inhibitors, which aim to effectively deliver a significant clinical response in patients with a triple mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.